Abbott Laboratories (ABT) vs peers in numbers

ABT and 9 peers, year by year

The 9 Health care companies closest to ABT in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

5 years 10 years Download CSV

Choose the peers

Each company's latest fiscal year
Company	Year	Revenue	Sales growth	Gross margin	Operating margin	Net margin	FCF margin	Return on equity	Debt / equity
ABT Abbott Laboratories	FY2025	$44.3B	+5.7%	-	18.2%	14.7%	16.7%	12.5%	0.25
TMO Thermo Fisher Scientific	FY2025	$44.6B	+3.9%	-	17.4%	15.0%	14.1%	12.6%	0.80
BMY Bristol Myers Squibb	FY2025	$48.2B	−0.2%	-	-	14.6%	26.7%	38.2%	2.55
AMGN Amgen	FY2025	$36.8B	+10.0%	-	24.7%	21.0%	22.0%	89.1%	6.31
MDT Medtronic	FY2026	$36.4B	+8.4%	-	17.8%	13.2%	14.9%	9.7%	0.57
PFE Pfizer	FY2025	$62.6B	−1.6%	-	-	12.4%	14.5%	9.0%	0.75
GILD Gilead Sciences	FY2025	$29.4B	+2.4%	-	34.0%	28.9%	32.1%	37.5%	1.10
ABBV AbbVie	FY2025	$61.2B	+8.6%	-	24.6%	6.9%	29.1%	n/m	n/m
MRK Merck & Co.	FY2025	$65.0B	+1.3%	-	-	28.1%	19.0%	34.7%	0.94
SYK Stryker Corporation	FY2025	$25.1B	+11.2%	64.0%	19.5%	12.9%	17.1%	14.5%	0.66

Revenuepeer median $44.6B

Sales growthpeer median +3.9%

Operating marginpeer median 22.1%

Net marginpeer median 14.6%

FCF marginpeer median 19.0%

Return on equitypeer median 24.6%

Debt / equitypeer median 0.87

AMGN 6.31
BMY 2.55
GILD 1.10
MRK 0.94
TMO 0.80
PFE 0.75
SYK 0.66
MDT 0.57
ABT 0.25
ABBV n/m

RevenueSales growthGross marginOperating marginNet marginFree cash flowFCF marginReturn on equityDebt / equityEPS (diluted)

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	$20.9B	$27.4B	$30.6B	$31.9B	$34.6B	$43.1B	$43.7B	$40.1B	$42.0B	$44.3B
TMO Dec	$18.3B	$20.9B	$24.4B	$25.5B	$32.2B	$39.2B	$44.9B	$42.9B	$42.9B	$44.6B
BMY Dec	$19.4B	$20.8B	$22.6B	$26.1B	$42.5B	$46.4B	$46.2B	$45.0B	$48.3B	$48.2B
AMGN Dec	$23.0B	$22.8B	$23.7B	$23.4B	$25.4B	$26.0B	$26.3B	$28.2B	$33.4B	$36.8B
MDT Apr	$28.8B	$29.7B	$30.0B	$30.6B	$28.9B	$30.1B	$31.7B	$31.2B	$32.4B	$33.5B
PFE Dec	$52.8B	$52.5B	$40.8B	$40.9B	$41.7B	$81.3B	$101.2B	$59.6B	$63.6B	$62.6B
GILD Dec	$30.4B	$26.1B	$22.1B	$22.4B	$24.7B	$27.3B	$27.3B	$27.1B	$28.8B	$29.4B
ABBV Dec	$25.6B	$28.2B	$32.8B	$33.3B	$45.8B	$56.2B	$58.1B	$54.3B	$56.3B	$61.2B
MRK Dec	$39.8B	$40.1B	$42.3B	$39.1B	$41.5B	$48.7B	$59.3B	$60.1B	$64.2B	$65.0B
SYK Dec	$11.3B	$12.4B	$13.6B	$14.9B	$14.4B	$17.1B	$18.4B	$20.5B	$22.6B	$25.1B
Peer median	$25.6B	$26.1B	$24.4B	$26.1B	$32.2B	$39.2B	$44.9B	$42.9B	$42.9B	$44.6B

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	+2.2%	+31.3%	+11.6%	+4.3%	+8.5%	+24.5%	+1.3%	−8.1%	+4.6%	+5.7%
TMO Dec	+7.7%	+14.5%	+16.4%	+4.9%	+26.1%	+21.7%	+14.5%	−4.6%	+0.1%	+3.9%
BMY Dec	+17.3%	+6.9%	+8.6%	+15.9%	+62.6%	+9.1%	−0.5%	−2.5%	+7.3%	−0.2%
AMGN Dec	+6.1%	−0.6%	+3.9%	−1.6%	+8.8%	+2.2%	+1.3%	+7.1%	+18.6%	+10.0%
MDT Apr	-	+3.0%	+0.8%	+2.0%	−5.4%	+4.2%	+5.2%	−1.4%	+3.6%	+3.6%
PFE Dec	-	−0.5%	+2.1%	+0.8%	+1.8%	+95.2%	+24.7%	−41.1%	+6.8%	−1.6%
GILD Dec	−6.9%	−14.1%	−15.2%	+1.5%	+10.0%	+10.6%	−0.1%	−0.6%	+6.0%	+2.4%
ABBV Dec	+12.2%	+10.1%	+16.1%	+1.6%	+37.7%	+22.7%	+3.3%	−6.4%	+3.7%	+8.6%
MRK Dec	-	+0.8%	+5.4%	+10.7%	+6.1%	+17.3%	+21.7%	+1.4%	+6.7%	+1.3%
SYK Dec	+13.9%	+9.9%	+9.3%	+9.4%	−3.6%	+19.2%	+7.8%	+11.1%	+10.2%	+11.2%
Peer median	+9.9%	+3.0%	+5.4%	+2.0%	+8.8%	+17.3%	+5.2%	−1.4%	+6.7%	+3.6%

Gross margin, FY2016 to FY2025

Gross profit / revenue.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	-	-	-	-	-	-	-	-	-	-
TMO Dec	-	-	-	-	-	-	-	-	-	-
BMY Dec	74.5%	70.7%	71.3%	69.1%	72.3%	-	-	-	-	-
AMGN Dec	-	-	-	-	-	-	-	-	-	-
MDT Apr	68.3%	68.7%	69.8%	-	-	-	-	-	-	-
PFE Dec	-	-	-	-	-	-	-	-	-	-
GILD Dec	-	-	-	-	-	-	-	-	-	-
ABBV Dec	-	-	-	-	-	-	-	-	-	-
MRK Dec	-	-	-	-	-	-	-	-	-	-
SYK Dec	66.3%	65.7%	65.7%	65.1%	63.1%	64.1%	62.8%	63.7%	63.9%	64.0%
Peer median	68.3%	68.7%	69.8%	-	-	-	-	-	-	-

Operating margin, FY2016 to FY2025

Operating income / revenue.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	14.5%	5.7%	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%
TMO Dec	13.5%	14.2%	15.5%	18.0%	24.2%	25.6%	18.7%	16.0%	17.1%	17.4%
BMY Dec	-	-	-	-	-	-	-	-	-	-
AMGN Dec	42.6%	43.6%	43.2%	41.4%	35.9%	29.4%	36.3%	28.0%	21.7%	24.7%
MDT Apr	18.6%	18.1%	22.2%	20.5%	16.6%	14.9%	18.2%	17.6%	15.9%	17.8%
PFE Dec	-	-	-	-	-	-	-	-	-	-
GILD Dec	58.0%	54.1%	37.1%	19.1%	16.5%	36.3%	26.9%	28.0%	5.8%	34.0%
ABBV Dec	36.4%	33.8%	19.5%	39.0%	24.8%	31.9%	31.2%	23.5%	16.2%	24.6%
MRK Dec	-	-	-	-	-	-	-	-	-	-
SYK Dec	19.2%	18.5%	18.7%	18.2%	15.5%	15.1%	15.4%	19.0%	16.3%	19.5%
Peer median	27.8%	26.1%	20.8%	19.8%	20.4%	27.5%	22.8%	21.2%	16.3%	22.1%

Net margin, FY2016 to FY2025

Net income / revenue.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	6.7%	1.7%	7.7%	11.6%	13.0%	16.4%	15.9%	14.3%	31.9%	14.7%
TMO Dec	11.1%	10.6%	12.1%	14.5%	19.8%	19.7%	15.5%	14.0%	14.8%	15.0%
BMY Dec	22.9%	4.8%	21.8%	13.2%	−21.2%	15.1%	13.7%	17.8%	−18.5%	14.6%
AMGN Dec	33.6%	8.7%	35.3%	33.6%	28.6%	22.7%	24.9%	23.8%	12.2%	21.0%
MDT Apr	12.3%	13.6%	10.4%	15.2%	16.6%	12.0%	15.9%	12.0%	11.4%	13.9%
PFE Dec	13.7%	40.6%	27.3%	39.2%	22.0%	27.0%	31.0%	3.6%	12.6%	12.4%
GILD Dec	44.4%	17.7%	24.7%	24.0%	0.5%	22.8%	16.8%	20.9%	1.7%	28.9%
ABBV Dec	23.2%	18.8%	17.4%	23.7%	10.1%	20.5%	20.4%	9.0%	7.6%	6.9%
MRK Dec	9.8%	6.0%	14.7%	25.2%	17.0%	26.8%	24.5%	0.6%	26.7%	28.1%
SYK Dec	14.5%	8.2%	26.1%	14.0%	11.1%	11.7%	12.8%	15.4%	13.2%	12.9%
Peer median	14.5%	10.6%	21.8%	23.7%	16.6%	20.5%	16.8%	14.0%	12.2%	14.6%

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	$2.1B	$4.4B	$4.9B	$4.5B	$5.7B	$8.6B	$7.8B	$5.1B	$6.4B	$7.4B
TMO Dec	$2.8B	$3.5B	$3.8B	$4.0B	$6.8B	$6.8B	$6.9B	$6.9B	$7.3B	$6.3B
BMY Dec	$1.8B	$4.2B	$6.1B	$7.4B	$13.3B	$15.2B	$11.9B	$12.7B	$13.9B	$12.8B
AMGN Dec	$9.6B	$10.5B	$10.6B	$8.5B	$9.9B	$8.4B	$8.8B	$7.4B	$10.4B	$8.1B
MDT Apr	$4.2B	$5.6B	$3.6B	$5.9B	$6.0B	$4.9B	$6.0B	$4.6B	$5.2B	$5.2B
PFE Dec	$14.4B	$14.8B	$13.8B	$10.5B	$12.2B	$29.9B	$26.0B	$4.8B	$9.8B	$9.1B
GILD Dec	$16.3B	$11.3B	$7.5B	$8.3B	$7.5B	$10.8B	$8.3B	$7.4B	$10.3B	$9.5B
ABBV Dec	$6.6B	$9.4B	$12.8B	$12.8B	$16.8B	$22.0B	$24.2B	$22.1B	$17.8B	$17.8B
MRK Dec	$8.8B	$4.6B	$8.3B	$10.1B	$5.8B	$8.7B	$14.7B	$9.1B	$18.1B	$12.4B
SYK Dec	$1.4B	$961.0M	$2.0B	$1.5B	$2.8B	$2.7B	$2.0B	$3.1B	$3.5B	$4.3B
Peer median	$6.6B	$5.6B	$7.5B	$8.3B	$7.5B	$8.7B	$8.8B	$7.4B	$10.3B	$9.1B

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	10.0%	16.2%	16.0%	14.1%	16.5%	20.1%	17.9%	12.6%	15.1%	16.7%
TMO Dec	15.4%	16.7%	15.5%	15.8%	21.2%	17.3%	15.4%	16.2%	16.9%	14.1%
BMY Dec	9.5%	20.3%	27.1%	28.2%	31.3%	32.8%	25.9%	28.1%	28.9%	26.7%
AMGN Dec	41.8%	46.0%	44.5%	36.5%	38.9%	32.3%	33.4%	26.1%	31.1%	22.0%
MDT Apr	14.5%	18.9%	12.1%	19.2%	20.8%	16.2%	18.9%	14.7%	16.1%	15.5%
PFE Dec	27.2%	28.3%	33.9%	25.8%	29.2%	36.7%	25.7%	8.0%	15.5%	14.5%
GILD Dec	53.6%	43.3%	33.8%	37.1%	30.5%	39.6%	30.6%	27.4%	35.8%	32.1%
ABBV Dec	25.6%	33.4%	39.0%	38.4%	36.7%	39.1%	41.8%	40.6%	31.7%	29.1%
MRK Dec	22.0%	11.4%	19.6%	25.7%	14.0%	17.8%	24.8%	15.2%	28.2%	19.0%
SYK Dec	12.6%	7.7%	15.0%	10.4%	19.4%	16.0%	11.0%	15.3%	15.4%	17.1%
Peer median	22.0%	20.3%	27.1%	25.8%	29.2%	32.3%	25.7%	16.2%	28.2%	19.0%

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	6.8%	1.5%	7.8%	11.9%	13.7%	19.8%	18.9%	14.8%	28.1%	12.5%
TMO Dec	9.4%	8.8%	10.7%	12.5%	18.5%	18.9%	15.8%	12.8%	12.8%	12.6%
BMY Dec	27.6%	8.6%	35.1%	6.7%	−23.8%	19.5%	20.4%	27.3%	−54.8%	38.2%
AMGN Dec	25.8%	7.8%	67.2%	81.1%	77.2%	88.0%	179.0%	107.8%	69.6%	89.1%
MDT Apr	6.8%	8.0%	6.1%	9.2%	9.4%	7.0%	9.6%	7.3%	7.3%	9.7%
PFE Dec	12.1%	29.9%	17.6%	25.4%	14.5%	28.5%	32.8%	2.4%	9.1%	9.0%
GILD Dec	71.5%	22.6%	25.5%	23.9%	0.7%	29.5%	21.6%	24.8%	2.5%	37.5%
ABBV Dec	128.4%	104.2%	n/m	n/m	35.3%	74.9%	68.6%	46.9%	128.7%	n/m
MRK Dec	9.8%	7.0%	23.3%	38.0%	27.9%	34.2%	31.6%	1.0%	37.0%	34.7%
SYK Dec	17.2%	10.2%	30.3%	16.3%	12.2%	13.4%	14.2%	17.0%	14.5%	14.5%
Peer median	17.2%	8.8%	24.4%	20.1%	14.5%	28.5%	21.6%	17.0%	12.8%	24.6%

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	1.07	0.90	0.64	0.58	0.57	0.50	0.46	0.38	0.30	0.25
TMO Dec	0.76	0.78	0.71	0.62	0.71	0.91	0.91	0.82	0.67	0.80
BMY Dec	0.41	0.62	0.49	0.96	1.39	1.37	1.39	1.34	3.15	2.55
AMGN Dec	1.16	1.40	2.71	3.09	3.51	4.97	10.64	10.37	10.23	6.31
MDT Apr	0.60	0.67	0.51	0.51	0.49	0.51	0.46	0.47	0.50	0.53
PFE Dec	0.62	0.61	0.64	0.81	0.07	0.49	0.37	0.81	0.72	0.75
GILD Dec	1.39	1.64	1.28	1.09	1.73	1.27	1.19	1.09	1.38	1.10
ABBV Dec	7.95	7.33	n/m	n/m	6.50	4.93	3.66	5.72	n/m	n/m
MRK Dec	0.62	0.71	0.94	1.02	1.26	0.87	0.67	0.93	0.80	0.94
SYK Dec	0.72	0.66	0.72	0.80	1.01	0.84	0.71	0.59	0.59	0.66
Peer median	0.72	0.71	0.72	0.89	1.26	0.91	0.91	0.93	0.76	0.87

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

Company	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
ABT Dec	$0.94	$0.27	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64	$3.72
TMO Dec	$5.09	$5.59	$7.24	$9.17	$15.96	$19.46	$17.63	$15.45	$16.53	$17.74
BMY Dec	$2.65	$0.61	$3.01	$2.01	−$3.99	$3.12	$2.95	$3.86	−$4.41	$3.46
AMGN Dec	$10.24	$2.69	$12.62	$12.88	$12.31	$10.28	$12.11	$12.49	$7.56	$14.23
MDT Apr	$2.48	$2.89	$2.27	$3.41	$3.54	$2.66	$3.73	$2.82	$2.76	$3.61
PFE Dec	$1.17	$3.52	$1.87	$2.82	$1.63	$3.85	$5.47	$0.37	$1.41	$1.36
GILD Dec	$9.94	$3.51	$4.17	$4.22	$0.10	$4.93	$3.64	$4.50	$0.38	$6.78
ABBV Dec	$3.63	$3.30	$3.66	$5.28	$2.72	$6.45	$6.63	$2.72	$2.39	$2.36
MRK Dec	$1.41	$0.87	$2.32	$3.81	$2.78	$5.14	$5.71	$0.14	$6.74	$7.28
SYK Dec	$4.35	$2.68	$9.34	$5.48	$4.20	$5.21	$6.17	$8.25	$7.76	$8.40
Peer median	$3.63	$2.89	$3.66	$4.22	$2.78	$5.14	$5.71	$3.86	$2.76	$6.78

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out ABT and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more →

Work on ABT in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ABT/export.csv") into a cell.

ABTAbbott Laboratories